Quantbot Technologies LP Buys 56,024 Shares of LifeMD, Inc. $LFMD

Key Points

• Quantbot Technologies LP increased its stake in LifeMD, Inc. by 467.6% in Q1, acquiring an additional 56,024 shares, bringing its total ownership to 68,006 shares valued at approximately $370,000.
• LifeMD's stock has experienced fluctuations, with a 1-year low of $3.99 and a high of $15.84, and currently has a market cap of $308.23 million.
• Insider trading has been significant, with notable sales including CFO Marc David Benathen offloading 50,000 shares for $700,500, reflecting a 12.84% decrease in his holdings.

Quantbot Technologies LP grew its holdings in LifeMD, Inc. (NASDAQ:LFMD - Free Report) by 467.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 68,006 shares of the company's stock after purchasing an additional 56,024 shares during the period. Quantbot Technologies LP owned about 0.15% of LifeMD worth $370,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of LifeMD in the 4th quarter valued at about $56,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of LifeMD by 17.3% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,412 shares of the company's stock valued at $235,000 after purchasing an additional 7,001 shares during the period. Northern Trust Corp increased its holdings in shares of LifeMD by 2.1% in the 4th quarter. Northern Trust Corp now owns 323,974 shares of the company's stock valued at $1,604,000 after purchasing an additional 6,634 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of LifeMD by 26.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company's stock valued at $70,000 after purchasing an additional 2,895 shares during the period. Finally, BNP Paribas Financial Markets acquired a new position in shares of LifeMD in the 4th quarter valued at about $279,000. Institutional investors and hedge funds own 35.52% of the company's stock.

Analyst Ratings Changes

LFMD has been the topic of a number of research reports. Wall Street Zen downgraded LifeMD from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. BTIG Research increased their price objective on LifeMD from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Wednesday, June 18th. Lake Street Capital dropped their price objective on LifeMD from $18.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, August 6th. HC Wainwright dropped their price objective on LifeMD from $14.00 to $13.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Finally, KeyCorp dropped their price objective on LifeMD from $14.00 to $12.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $13.17.

Insiders Place Their Bets

In related news, CEO Justin Schreiber sold 25,000 shares of the firm's stock in a transaction on Tuesday, July 1st. The stock was sold at an average price of $13.38, for a total value of $334,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,500,721 shares of the company's stock, valued at $33,459,646.98. This trade represents a 0.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Stefan Galluppi sold 85,000 shares of the firm's stock in a transaction on Friday, June 13th. The stock was sold at an average price of $12.38, for a total value of $1,052,300.00. Following the completion of the transaction, the insider directly owned 80,449 shares of the company's stock, valued at approximately $995,958.62. This trade represents a 51.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 275,000 shares of company stock valued at $3,564,550 over the last ninety days. 18.40% of the stock is owned by insiders.

LifeMD Stock Performance

LFMD stock traded down $0.27 during midday trading on Friday, hitting $6.19. 1,053,488 shares of the company traded hands, compared to its average volume of 2,855,993. LifeMD, Inc. has a twelve month low of $3.99 and a twelve month high of $15.84. The company has a quick ratio of 0.72, a current ratio of 0.77 and a debt-to-equity ratio of 9.21. The business has a 50 day simple moving average of $9.86 and a 200-day simple moving average of $8.53. The stock has a market capitalization of $293.53 million, a price-to-earnings ratio of -29.48 and a beta of 1.72.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.